Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LIXTW 
Lixte Biotechnology Holdings Inc (LIXTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LIXTW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -68% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.49M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.02 - 0.09 | Updated Date 06/21/2025 |
52 Weeks Range 0.02 - 0.09 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.14% | Return on Equity (TTM) -155.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 2527941 |
Shares Outstanding - | Shares Floating 2527941 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc
Company Overview
History and Background
Lixte Biotechnology Holdings Inc., was incorporated in 2005. It focuses on the discovery, development, and commercialization of novel therapies for cancer and other diseases. The company is headquartered in East Setauket, New York.
Core Business Areas
- Clinical Development: Focuses on advancing clinical trials for lead compound LB-100, a protein phosphatase 2A (PP2A) activator, in various cancer types.
- Research and Development: Conducts research to identify new drug candidates and expand the applications of existing compounds.
Leadership and Structure
Dr. John S. Kovach serves as the CEO and Founder. The company has a board of directors overseeing its strategic direction and operations.
Top Products and Market Share
Key Offerings
- LB-100: LB-100 is Lixte's lead drug candidate, a protein phosphatase 2A (PP2A) activator being investigated in multiple clinical trials for different cancers. Market share data is not publicly available. Competitors include companies developing targeted therapies and immunotherapies for similar cancer indications.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. There is a growing focus on precision medicine and targeted therapies.
Positioning
Lixte Biotechnology is positioned as a developer of novel therapies based on PP2A modulation. Its competitive advantage lies in its proprietary compound LB-100 and its potential to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is billions of dollars annually. Lixte is focusing on specific cancer subtypes, addressing a portion of the total market. Success in clinical trials could significantly expand their market reach.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (PP2A activation)
- Promising preclinical and early clinical trial results for LB-100
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on single drug candidate (LB-100)
- Relatively small size compared to major pharmaceutical companies
Opportunities
- Positive clinical trial outcomes leading to regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion of LB-100 indications to other cancer types
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Lixte operates in a highly competitive landscape dominated by large pharmaceutical companies. Its advantage lies in its novel approach to cancer therapy, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by progress in clinical trials for LB-100 and potential partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely due to the uncertainty inherent in biotechnology development.
Recent Initiatives: Recent initiatives include progressing LB-100 through ongoing clinical trials and seeking potential collaborations.
Summary
Lixte Biotechnology Holdings Inc. is a high-risk, high-reward biotechnology company focused on developing LB-100 for cancer treatment. Its strength lies in the novel mechanism of action, but its weaknesses include limited resources and dependence on a single drug. Successful clinical trials and strategic partnerships are critical for future success and to stay competitive in a landscape dominated by major pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Financial news sources (e.g., Yahoo Finance)
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2020-11-25 | CEO & Chairman Mr. Geordan G. Pursglove | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com | ||
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.